Table 1.
Demographic and clinical characteristics.
| Clinicopathologic Characteristic | PCS (n = 128) |
NACT (n = 172) |
p | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Age | 0.625 | ||||
| Median (range) | 61 (24–83) | 62 (25–95) | |||
| Race/ethnicity | 0.500 | ||||
| White | 97 | 75.8 | 123 | 72.4 | |
| African American/Black | 5 | 3.9 | 13 | 7.6 | |
| Asian | 9 | 7.0 | 15 | 8.8 | |
| Hispanic | 17 | 13.3 | 19 | 11.2 | |
| Unknown | 0 | 0 | 2 | N/A | |
| Disease site | 0.022 | ||||
| Fallopian tube | 10 | 7.9 | 6 | 3.5 | |
| Ovary | 95 | 75.4 | 117 | 68 | |
| Peritoneum | 21 | 16.7 | 49 | 28.5 | |
| Unknown | 2 | N/A | 0 | 0 | |
| Stage | <0.001 | ||||
| In Situ | 1 | 0.8 | 0 | 0.0 | |
| I | 11 | 9.2 | 0 | 0.0 | |
| II | 13 | 10.8 | 1 | 0.7 | |
| III | 82 | 68.3 | 72 | 53.3 | |
| IV | 13 | 10.8 | 60 | 44.4 | |
| Advanced | 0 | 0.0 | 2 | 1.5 | |
| Unknown/unstaged | 8 | N/A | 37 | N/A | |
| Histology | <0.001 | ||||
| Serous | |||||
| High grade | 92 | 71.9 | 155 | 90.1 | |
| Low grade | 16 | 12.5 | 12 | 6.9 | |
| Endometrioid | |||||
| High grade | 8 | 6.2 | 1 | 0.6 | |
| Low grade | 1 | 0.8 | 0 | 0.0 | |
| Clear cell | 9 | 7.0 | 2 | 1.2 | |
| Adenocarcinoma NOS | 2 | 1.6 | 2 | 1.2 | |
| Cytoreductive surgery | 0.356 | ||||
| Optimal | 103 | 92.0 | 139 | 88.5 | |
| R0 | 70 | 68.0 | 90 | 57.3 | |
| ≤1 cm | 18 | 16.1 | 29 | 18.5 | |
| Not specified | 15 | 13.4 | 20 | 12.7 | |
| Suboptimal (>1 cm) | 9 | 8.0 | 18 | 11.5 | |
| Unknown | 16 | N/A | 15 | N/A | |
| Follow-up (months) | 0.870 | ||||
| Alive at time of analysis | 68 | 53.1% | 45 | 26.2% | |
| Median (range) | 79.1 (18.6–114.9) | 79.2 (9.3–105.4) | |||
N/A = not applicable. NACT = neoadjuvant chemotherapy. NOS = not otherwise specified. PCS = primary cytoreductive surgery. R0 = no macroscopic residual tumor. Note: cases with “unknown” characteristics are not included in percentages shown. N/A = not applicable. NACT = neoadjuvant chemotherapy. NOS = not otherwise specified. PCS = primary cytoreductive surgery. R0 = no macroscopic residual tumor.